M. Deleuran, “Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use”, Acta Derm Venereol, vol. 101, no. 7, p. adv00504, Jul. 2021.